rheumatoid arthritis
Conditions
Interventions
tocilizmab
Sponsors
Itabashi Chuo Medical Center
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: All RA patients were recruited at our center from December 2010 to May 2012. All patients met the 2010 American College of Rheumatology/European League Against Rheumatism criteria for RA. Moderate to severe active RA patients [using the Disease Activity Score in 28 joints (DAS28) ; cut off 3.2] receiving methotrexate (MTX) who were candidates for tocilizumab (TCZ) without prior use of any biologic were included in the study.
Exclusion criteria
Exclusion criteria: Participants were excluded if they had prior self-reported, physician-diagnosed cardiovascular events or procedures, such as myocardial infarction, angioplasty, and congestive heart failure. Additional exclusions were diabetes (HbA1c>6.1), hypertension ((systolic blood pressure (BP) >140 mm Hg and/or diastolic BP>90 mm Hg), and dyslipidemia (LDL cholesterol levels are greater than 140 mg/dL, an HDL cholesterol level<40 mg/dL, or a triglyceride level>150 mg/dL).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We explored the associations of cardiac MRI abnormalities with RA disease activity and severity measures. | — |
Secondary
| Measure | Time frame |
|---|---|
| To detect the influence of Biologics in cardiac function | — |
Countries
Japan
Contacts
Public ContactIsamu Yokoe
internal medicine rheumatology
Outcome results
None listed